Psoriasis

Plaque Psoriasis
#Dermatology #Phase III trial #Psoriasis #Takeda

Landmark results support TYK2 inhibitor as a leading psoriasis treatment

Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) has shown promise to deliver clear skin in a once-daily pill.  Phase III studies in adults with moderate-to-severe plaque psoriasis (PsO) have demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA)… Read More

#News

Plaque Psoriasis
#Dermatology #FDA #Plaque Psoriasis #Psoriasis

FDA approves new first-line therapy for plaque psoriasis

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s allosteric tyrosine kinase 2 inhibitor Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. It is approved in patients who are candidates for systemic therapy or phototherapy, but not recommended in combination with other potent immunosuppressants. Read More

#News